Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors - Trial NCT05917145
Access comprehensive clinical trial information for NCT05917145 through Pure Global AI's free database. This Phase 1 trial is sponsored by Mayo Clinic and is currently Not yet recruiting. The study focuses on Glioblastoma. Target enrollment is 67 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mayo Clinic
Timeline & Enrollment
Phase 1
Sep 15, 2023
Oct 15, 2028
Primary Outcome
Determine the maximum tolerated dose of WSD0628 in combination with radiation therapy for patients with recurrent high-grade glioma.,Determine the recommended phase 2 dose of WSD0628 in combination with radiation therapy for patients with recurrent high-grade glioma.
Summary
The purpose of this study is to test WSD0628 in combination with radiation therapy for
 recurrent brain tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05917145
Non-Device Trial